{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:21:20Z","timestamp":1788304880044,"version":"build-2803163510"},"reference-count":38,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Biochem &amp;amp; Molecular Tox"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Capmatinib and tepotinib are selective MET inhibitors for MET exon 14 skipping non\u2010small cell lung cancer (NSCLC), yet comprehensive real\u2010world safety profiles, particularly concerning respiratory and rare adverse events (AEs), remain limited. We conducted a disproportionality analysis of the FDA AE Reporting System (FAERS) database, utilizing four algorithms (ROR, PRR, BCPNN, MGPS) to identify AE signals from 1771 cases for capmatinib and 470 for tepotinib, standardized with MedDRA v26.0. Both inhibitors shared signals for systemic AEs, such as peripheral oedema and gastrointestinal disorders. However, their respiratory AE profiles diverged: capmatinib was associated with pleural effusion and pulmonary oedema, whereas tepotinib was linked to infectious complications, including interstitial lung disease and infectious pleural effusion. Importantly, we identified significant novel signals beyond current drug labels: sensory disturbances, and thrombosis for capmatinib; and fluid imbalance\u2010related events for tepotinib. These distinct AE profiles highlight an infection\u2010driven pulmonary risk for tepotinib requiring close monitoring, while capmatinib's association with sensory disorders warrants specific patient management considerations. Our findings underscore the need for individualized safety monitoring based on the unique AE profiles of each MET inhibitor.<\/jats:p>","DOI":"10.1002\/jbt.70657","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:13:00Z","timestamp":1766571180000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6888-4752","authenticated-orcid":false,"given":"Xing","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital Medical Center of Soochow University Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danyan","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital Medical Center of Soochow University Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital Medical Center of Soochow University Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Affiliated Suzhou Hospital of Nanjing Medical University Suzhou Municipal Hospital Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital Medical Center of Soochow University Suzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw262"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0285"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2025.01.013"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0377-z"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0716-8"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194779"},{"key":"e_1_2_13_10_1","unstructured":"\u201cFDA Approves First Targeted Therapy to Treat Aggressive Form of Lung Cancer\u201d. FDA accessed May 6 2020 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-treat-aggressive-form-lung-cancer."},{"key":"e_1_2_13_11_1","unstructured":"\u201cFDA Approves Tepotinib for Metastatic Non\u2010Small Cell Lung Cancer\u201d. FDA accessed February 15 2024 https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-tepotinib-metastatic-non-small-cell-lung-cancer."},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00441-8"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103668"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jamia\/ocv153"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2235267"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2410436"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1333662"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1438292"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S528454"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2113"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02801-3"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.677"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01454-0"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107897"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1446"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.06.020"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107934"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2004407"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.05.037"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.03.021"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1188\/20.CJON.566-570"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.01.003"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2018.11.005"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01863-w"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06549.x"},{"key":"e_1_2_13_38_1","first-page":"33","article-title":"Spotlight on Tepotinib and Capmatinib for Non\u2010Small Cell Lung Cancer With MET Exon 14 Skipping Mutation","volume":"13","author":"Brazel D.","year":"2022","journal-title":"Lung Cancer (Auckland, N.Z.)"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2814"}],"container-title":["Journal of Biochemical and Molecular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbt.70657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jbt.70657","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jbt.70657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:28:21Z","timestamp":1777552101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jbt.70657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/jbt.70657"],"URL":"https:\/\/doi.org\/10.1002\/jbt.70657","archive":["Portico"],"relation":{},"ISSN":["1095-6670","1099-0461"],"issn-type":[{"value":"1095-6670","type":"print"},{"value":"1099-0461","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"2025-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70657"}}